Search Bar & Filters
Found 976 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
This research aims to evaluate how a structured productivity training program affects nurses perceived job stress and their attitudes toward productivity. The study is designed as a randomized controlled experimental trial with assessments before the training, immediately after, and three months later. Researchers want to see if nurses who receive the training report lower stress and better productivity attitudes compared to those who do not. The study involves two groups an experimental group that receives a three-week productivity training totaling 20 hours, and a control group that receives no training during the same period. The training covers nursing productivity concepts, time and stress management, teamwork, leadership, digital tools, and coping with job stress. Various teaching methods like lectures, case studies, simulations, and group work are used to improve cognitive, emotional, and practical skills. Participants will complete assessments using the Nurses Attitudes Toward Productivity Scale and the Perceived Job Stress Scale at three time points before training, right after the training, and three months later. The control group also completes these assessments without receiving training during the study but will get access to the training materials afterward. The total study duration includes the training period plus follow-up assessments to monitor lasting effects.
Actively Recruiting
This observational study investigates how self-compassion and self-efficacy relate to symptom severity, functional ability, and quality of life in adults diagnosed with Parkinsons disease. The research aims to better understand these psychological factors in people living with Parkinsons disease stages 1 to 3, within an age range of 40 to 85 years. Participants will complete a set of self-report questionnaires during one session to assess their levels of self-compassion, self-efficacy, symptom severity, functional status, and quality of life. No therapeutic treatments or interventions are provided. The study collects data at a single time point to analyze associations among these outcomes. During the study visit, participants will be assessed with various scales and tests including the Self-Compassion Scale, Self-Efficacy for Managing Chronic Disease scale, Unified Parkinsons Disease Rating Scale, Timed Up and Go test, Six-Minute Walk test, Mini-Balance Evaluation Systems Test, and Parkinsons Disease Questionnaire-39. These assessments help evaluate physical function, symptoms, and quality of life. The study is led by Acibadem University and participation involves completing questionnaires and physical tests in one session.
Actively Recruiting
Researchers are evaluating the Turkish version of the Heat Sensitivity Scale in individuals with Parkinsons disease. This cross-sectional observational study aims to examine the scales validity and reliability, including its internal consistency, test-retest reliability, and construct validity. The goal is to provide a trustworthy tool for assessing temperature sensitivity in Turkish-speaking people diagnosed with Parkinsons disease aged 40 to 85. Participants will complete assessments that include the Heat Sensitivity Scale and the Parkinsons Disease Questionnaire-39 PDQ-39. These measurements will be taken at baseline to evaluate their psychometric properties. No interventions or treatments are administered as part of this observational study. During the study, participants will attend assessments at the Movement Disorders Outpatient Clinic, where cognitive and communication abilities will be evaluated to ensure they can complete the questionnaires. Researchers will measure the Heat Sensitivity Scale total score and PDQ-39 total and subscale scores at the time of questionnaire completion. The study spans from May 2026 to May 2027, with the primary outcome measured at baseline.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.
Actively Recruiting
Healthy Volunteer
This clinical trial studies children aged 6 to 12 with maxillary transverse deficiency, a condition causing dental crowding and crossbite. It compares two methods of maxillary expansion a traditional Rapid Maxillary Expansion RME using an acrylic cap splint with daily screw activations, and a modern digital Invisalign Palatal Expander IPE made with 3D printing that fits the palate and activates in smaller steps. The trial also includes a control group that does not receive expansion treatment. Participants are randomly assigned to three groups IPE, RME, or untreated controls. The IPE is a removable nylon device activated at 0.25 mm per step, while RME uses a bonded acrylic splint with a screw activated at 0.5 mm per day. Both treatment groups undergo expansion followed by retention. The control group receives no treatment during the study period. Three-dimensional intraoral and extraoral scans are taken at the end of expansion, at 3 months, and at 6 months. Participants will have scans to measure maxillary arch width, first molar angulation, palatal surface area, palatal volume, and facial soft tissue changes over time. These assessments help compare the effects of the two expansion methods and the untreated group. The study aims to provide evidence to guide orthodontic care in children with this condition. The total study duration extends through the 6-month retention period after expansion.
Actively Recruiting
Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.
Actively Recruiting
Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.
Actively Recruiting
Researchers are studying calderasib alone and in combination with cetuximab to treat advanced solid tumors in people with the KRAS G12C mutation. The study aims to find out how many patients respond to these treatments and to evaluate their safety and tolerability. This phase 2 trial is tumor-agnostic, meaning it includes various solid tumors except colorectal cancer that have progressed despite standard treatment. Participants receive calderasib by mouth, either alone or with cetuximab given by intravenous infusion every two weeks. There is no set maximum number of treatment cycles, and participants continue until they meet criteria to stop treatment. The study is randomized and open-label, comparing the two treatment approaches in parallel groups. During the study, participants will be monitored for tumor response, adverse events, and reasons for discontinuing treatment over about 76 months. Researchers will assess progression-free survival, duration of response, and overall survival. Safety evaluations and regular clinical visits will support ongoing monitoring throughout the trial.
Actively Recruiting
Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.
Actively Recruiting
Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.
1-10 of 976
1